Interferon beta-1a

Therapeutic indications

Interferon beta-1a is indicated for:

Relapsing multiple sclerosis (MS)

Population group: only adults (18 years old or older)

Interferon beta-1a is indicated for the treatment of:

Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three-years without evidence of continuous progression between relapses; Interferon beta-1a slows the progression of disability and decreases the frequency of relapses.
Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

Interferon beta-1a should be discontinued in patients who develop progressive MS.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

7.5-30 ug once a week

Contraindications

Interferon beta-1a is contraindicated in the following cases:

Severe depression, suicidal ideation

at least one of

Severe depression
Suicidal ideation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.